Artificial Intelligence

Natera's Signatera test salvaged key insights from a failed clinical trial, creating a new roadmap for personalized breast cancer treatment and logistics.

Ancient remedies meet modern AI. See how companies are using data and smart factories to transform traditional Chinese medicine into a global pharma force.

A new partnership uses AI to analyze imaging, clinical, and molecular data, offering unprecedented accuracy in predicting breast cancer recurrence years later.

An energy services giant just sold its nuclear arm to a startup in a stock deal. It's a strategic pivot to mass-produce reactors for the AI power crunch.

Serve Robotics and Uber Eats launch sidewalk robots in Alexandria, Va., testing the scalability, economics, and public acceptance of last-mile automation.

Serina Therapeutics has answered the FDA's challenge. A 30-day clock now ticks on its novel Parkinson's therapy and its disruptive drug delivery platform.

Gemini's new license to offer prediction markets signals a major regulatory shift, but it also wades into a turbulent world of ethical and legal challenges.

A new pact on quantum computing and AI safety aims to do more than innovate—it seeks to build a secure, equitable digital world for every citizen.

A $3 billion drop in assets at AllianceBernstein, driven by client withdrawals in a flat market, signals a deeper challenge for active asset managers.

Beyond the headlines of a $592M debt reduction, McGraw Hill is executing a dual strategy: fortifying its finances to fund a digital and AI-driven future.

Early trial data suggests GRI-0621 could be a game-changer for Idiopathic Pulmonary Fibrosis, showing lung repair and a much better safety profile.

BridgeBio Oncology's new drug candidate BBO-10203 could redefine cancer therapy by avoiding a key toxicity, unlocking a vast market.

Aardvark Therapeutics' pivotal trial for Prader-Willi syndrome goes global, a key step toward commercializing its novel hunger-suppressing drug.

A small biotech is challenging oncology's giants with a drug that targets cancer's core weakness, offering new hope to the sickest lung cancer patients.

Micro-cap BSEG racks up awards against giants like Variety, but with a volatile stock and weak fundamentals, can creative success spark a financial turnaround?

Canada adds four groups to its terror list, taking a bold stand against online networks preying on youth and global insurgencies. Here's what it means.

A $2M non-dilutive facility is helping Luminit scale its holographic optics production, a key move to dominate the booming AR-HUD market in auto and defense.

Vision Fortune Finance Institute unveils a powerful new data engine for its Nexus AI, aiming to revolutionize financial research by taming data overload.

The eyewear giant is moving beyond frames, partnering to design custom chips. A strategic pivot to open-source hardware aims to redefine the market.

UST's acquisition of Italdesign from Audi Group signals a new era where AI and software are as crucial as chassis and steel in automotive innovation.